Filings/ZYDUSLIFE/IR

ZYDUS LIFESCIENCES LIMITED IR

press release

Zydus announces positive Phase 2 Proof-of-Concept of NLRP3 inhibitor, ZYIL1 in patients with Cryopyrin Associated Periodic Syndrome (CAPS) - 07/09/2022

Source document

Issuer site
Loading document…
Zydus announces positive Phase 2 Proof-of-Concept of NLRP3 inhibitor, ZYIL1 in patients with Cryopyrin Associated Periodic Syndrome (CAPS) - 07/09/2022 — ZYDUS LIFESCIENCES LIMITED